When it comes to fighting super villains, the world of comic books is filled with unexpected collaborations. A new team-up of Takeda Pharmaceutical and Marvel Custom Solutions has risen to empower those who face the daily challenges of inflammatory bowel disease.

As part of its strategic review and second-quarter 2017 financial reporting, Ardelyx announced the company planned to cut 28 percent of its workforce.

Two have been around in the pharmaceutical industry for a long time, and one is a relative newcomer. In considering this year’s pharma innovators to profile, the results of their accomplishments, not how long they have been around, steered the direction of this feature. Donna Murphy, global CEO of the recently formed agency network Havas Health & You; Abraham Gutman, president and CEO of AG Mednet; and C. David Nicholson, executive VP and chief R&D officer of Allergan, are being saluted for bringing new innovations to the fields of pharmaceutical advertising, clinical trial imaging and R&D, and their accomplishments are expected to echo into the future.

Ironwood Pharmaceuticals touted its Phase IIb drug candidate IW-3718 in adult patients with uncontrolled gastroesophageal reflux disease (GERD), but investors seem wary as share prices were down more than 7 percent.

J&J subsidiary Janssen inked a collaboration deal to develop Protagonist Therapeutics’ PTG-200 for various gastrointestinal diseases.

Synergy Pharmaceuticals’ experimental once-daily tablet plecanatide met the main goal of a late-stage study on irritable bowel syndrome patients with constipation.

Allergan struck a $200 million deal to snag Motus Therapeutics in an effort to shore up its gastrointestinal therapies.

Agency leaders talk about their favorite DTC campaigns of the past year.

  11 billion euro R&D programme through 2020, with 5 billion euro dedicated to pre-clinical R&D and 1.5 billion euro planned for cooperation with external partners New partnerships with the Icahn School of Medicine at Mount Sinai, Massachusetts General Hospital, the Scripps Research Institute and Weill Cornell Medicine to discover new treatments for inflammatory bowel […]